5384-09-8

Upstream product

• 51233-80-8 2,6-dimethylphenyl propionate 
• 576-26-1 2.6-dimethylphenol 
• 79-03-8 propionyl chloride 
• 73049-11-3 (3,5-dimethyl-4-hydroxyphenyl)-ethylcarbinol 

Downstream Products

• 13037-82-6 2-Hydroxy-1.3-dimethyl-5-propyl-benzol 
• 73049-11-3 (3,5-dimethyl-4-hydroxyphenyl)-ethylcarbinol 
• 1939-69-1 1-[4-(2,3-Dihydroxy-propoxy)-3,5-dimethyl-phenyl]-propan-1-one 
• 92368-88-2 2,6-Dimethyl-4-propyl-phenyl-propyl-aether 
• 92726-50-6 1-[4-(2-Dimethylamino-ethoxy)-3,5-dimethyl-phenyl]-propan-1-one 

Relevant academic research and scientific papers

COMBINATIONS FOR THE TREATMENT OF PARKINSONISM CONTAINING SELECTIVE NMDA ANTAGONISTS

This invention relates to a method of treating Parkinson's Disease whereby a mammal suffering from Parkinson's Disease is treated with a combination of a forebrain selective NMDA antagonist and a compound which is capable of increasing the excitatory feedback from the ventral lateral nucleus of the thalamus into the cortex. This invention also relates to pharmaceutical compositions containing the synergistic combination.

Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydroxyphenyl)-2-(piperidinyl-1)-alkanol derivatives

PCT No. PCT/IB95/00380 Sec. 371 Date Feb. 13, 1996 Sec. 102(e) Date Feb. 13, 1996 PCT Filed May 18, 1995 PCT Pub. No. WO96/06081 PCT Pub. Date Feb. 29, 1996This invention relates to compounds of formula (I), or pharmaceutically acceptable acid addition salts thereof, wherein: (a) R2 and R5 are taken separately and R1, R2, R3 and R4 are each independently hydrogen, (C1-C6) alkyl, halo, CF3, OH or OR7 and R5 is methyl or ethyl; or (b) R2 and R5 are taken together, forming a chroman-4-ol ring, and R1, R3 and R4 are each independently hydrogen, (C1-C6) alkyl, halo, CF3, OH or OR7; and R6 is a substituted piperidinyl, pyrrolidinyl or 8-azabicyclo(3.2.1)octanyl derivative; provided that (a) when R2 and R5 are taken separately, at least one of R1, R2, R3 and R4 is not hydrogen; and (b) when R2 and R5 are taken together, at least one of R1, R3 and R4 is not hydrogen; pharmaceutical compositions thereof; and methods of treating mammals suffering from stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, CNS degenerative diseases such as Alzheimer's disease, senile dementia of the Alzheimer's type, Huntington's disease, Parkinson's disease, epilepsy, amyotrophic lateral sclerosis, pain, AIDS dementia, psychotic conditions, drug addictions, migraine, hypoglycemia, anxiolytic conditions, urinary incontinence and an ischemic event arising from CNS surgery, open heart surgery or any procedure during which the function of the cardiovascular system is compromised with a compound of formula (I) hereinabove or a pharmaceutically acceptable salt thereof.

Quinone Dehydrogenation. Oxidation of Benzylic Alcohols with 2,3-Dichloro-5,6-dicyanobenzoquinone

2,3-Dichloro-5,6-dicyanobenzoquinone (DDQ) reacts with primary and secondary aryl-substituted alcohols under mild conditions in dioxane solution to give the corresponding carbonyl compounds in high yields.In contrast to other oxidants, DDQ can be applied advantageously for the oxidation of hydroxyaryl-substituted alcohols.A mechanism involving participation of the phenolic hydroxyl group in the dehydrogenation reaction is discussed.Oxidations of hydroxyaryl-substituted alcohols by DDQ in methanolsolution resulting in the formation of benzoquinones by loss of the hydroxyaryl side chain are interpreted in terms of phenol oxidation.An example of a pyridine-catalyzed Smiles rearrangement of an o-hydroxy-substituted diphenyl ether is reported.